SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-004830 to DYADIC INTERNATIONAL INC (DYAI)

DYADIC INTERNATIONAL INC
Date: April 30, 2024 · CIK: 0001213809 · Accession: 0000000000-24-004830

AI Filing Summary & Sentiment

File numbers found in text: 333-278916

Date
April 30, 2024
Author
Not clearly detected
Form
UPLOAD
Company
DYADIC INTERNATIONAL INC

Letter

United States securities and exchange commission logo April 30, 2024 Mark Emalfarb Chief Executive Officer Dyadic International, Inc. 1044 North U.S. Highway One, Suite 201 Jupiter, FL 33477 Re:Dyadic International, Inc. Registration Statement on Form S-3 Filed April 24, 2024 File No. 333-278916 Dear Mark Emalfarb: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jessica Chen, Esq.

Show Raw Text
United States securities and exchange commission logo
April 30, 2024
Mark Emalfarb
Chief Executive Officer
Dyadic International, Inc.
1044 North U.S. Highway One, Suite 201
Jupiter, FL 33477
Re:Dyadic International, Inc.
Registration Statement on Form S-3
Filed April 24, 2024
File No. 333-278916
Dear Mark Emalfarb:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Jessica Chen, Esq.